Category «PHASE 3»

It’s only fair to share… Relacorilant Molecular FormulaC27H22F4N6O3S Average mass586.561 Da CAS 1496510-51-0 Phase III UNII-2158753C7E 2158753C7E [(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone [(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone Methanone, [(4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)-2-pyridinyl]- Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)- релакорилант [Russian] [INN] ريلاكوريلانت [Arabic] [INN] 瑞拉可兰 [Chinese] [INN] OriginatorCorcept Therapeutics ClassAntineoplastics; Fluorine compounds; Isoquinolines; Ketones; Organic sulfur compounds; Pyrazoles; Pyridines; Small molecules Mechanism of ActionGlucocorticoid receptor antagonists Orphan Drug StatusYes – Pancreatic cancer; Cushing syndrome Phase IIICushing syndrome; …

Read more

It’s only fair to share… TEREVALEFIM Molecular Formula C9-H8-N2-S Molecular Weight 176.2382 RN: 1070881-42-3 UNII: GG91UXK2M5 5-((E)-2-Thiophen-2-yl-vinyl)-lh-pyrazole 1H-Pyrazole, 3-((1E)-2-(2-thienyl)ethenyl)- ANG-3777 SNV-003 OriginatorAngion Biomedica ClassAnti-ischaemics; Antifibrotics; Heart failure therapies; Pyrazoles; Small molecules; Thiophenes; Urologics; Vascular disorder therapies Mechanism of ActionProto oncogene protein c met stimulants Orphan Drug StatusYes – Renal failure Phase IIIDelayed graft function Phase IIAcute kidney …

Read more

It’s only fair to share… COBITOLIMOD IUPAC Condensed dGuo-sP-dGuo-sP-dAdo-sP-dAdo-P-dCyd-P-dAdo-P-dGuo-P-dThd-P-dThd-P-dCyd-P-dGuo-P-dThd-P-dCyd-P-dCyd-P-dAdo-P-dThd-sP-dGuo-sP-dGuo-sP-dCyd Sequence GGAACAGTTCGTCCATGGC HELM RNA1{[dR](G).[sp][dR](G).[sp][dR](A).[sp][dR](A).P[dR](C).P[dR](A).P[dR](G).P[dR](T).P[dR](T).P[dR](C).P[dR](G).P[dR](T).P[dR](C).P[dR](C).P[dR](A).P[dR](T).[sp][dR](G).[sp][dR](G).[sp][dR](C)}$$$$ IUPAC 2′-deoxy-P-thio-guanylyl-(3′->5′)-2′-deoxy-P-thio-guanylyl-(3′->5′)-2′-deoxy-P-thio-adenylyl-(3′->5′)-2′-deoxy-adenylyl-(3′->5′)-2′-deoxy-cytidylyl-(3′->5′)-2′-deoxy-adenylyl-(3′->5′)-2′-deoxy-guanylyl-(3′->5′)-thymidylyl-(3′->5′)-thymidylyl-(3′->5′)-2′-deoxy-cytidylyl-(3′->5′)-2′-deoxy-guanylyl-(3′->5′)-thymidylyl-(3′->5′)-2′-deoxy-cytidylyl-(3′->5′)-2′-deoxy-cytidylyl-(3′->5′)-2′-deoxy-adenylyl-(3′->5′)-P-thio-thymidylyl-(3′->5′)-2′-deoxy-P-thio-guanylyl-(3′->5′)-2′-deoxy-P-thio-guanylyl-(3′->5′)-2′-deoxy-cytidine   [(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl] hydrogen phosphate DNA, d(G-sp-G-sp-A-sp-A-C-A-G-T-T-C-G-T-C-C-A-T-sp-G-sp-G-sp-C) Molecular Formula, C185-H233-N73-O106-P18-S6 Molecular Weight 5925.2087 MF C185H233N73O106P18S6 CAS 1226822-98-5 WHO 10066, IDX 0150, DIMS 0150, Kappaproct Treatment of Moderate to Severe Ulcerative Colitis DNA based oligonucleotide that activates toll-like receptor 9. UNII: 328101264R DNA, d(g-SP-g-SP-a-SP-a-c-a-g-t-t-c-g-t-c-c-a-t-SP-g-SP-g-SP-C) …

Read more

It’s only fair to share… IUPAC Condensed cyclo[Arg-Gly-Asp-D-Phe-N(Me)Val] HELM PEPTIDE1{R.G.D.[dF].[meV]}$PEPTIDE1,PEPTIDE1,5:R2-1:R1$$$ IUPAC cyclo[L-arginyl-glycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl]     CILENGITIDE Molecular FormulaC27H40N8O7 Average mass588.656 Da 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid 188968-51-6 [RN] 4EDF46E4GI 7823 циленгитид سيلانجيتيد 西仑吉肽 EMD 121974, EMD-121974, UNII-4EDF46E4GI 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid Cilengitide has been in phase III clinical trials by Merck Serono and NCI for the treatment of glioblastoma multiforme. However, this research has been …

Read more

It’s only fair to share… Verdiperstat AZD 3241; BHV-3241 CAS No. : 890655-80-8 1-(2-propan-2-yloxyethyl)-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1,2,3,5-tetrahydro-1-[2-(1-methylethoxy)ethyl]-2-thioxo- 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one l-(2-Isopropoxyethyl)-2-thioxo-l,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one Molecular FormulaC11H15N3O2S Average mass253.321 Da AZD-3241, BHV-3421, UNII-TT3345YXVR, TT3345YXVR, BHV-3241, WHO 10251 вердиперстат [Russian] [INN] فيرديبيرستات [Arabic] [INN] 维地泊司他 [Chinese] [INN] OriginatorAstraZeneca DeveloperAstraZeneca; Biohaven Pharmaceuticals ClassAntiparkinsonians; Ethers; Organic sulfur compounds; Pyrimidinones; Small molecules Mechanism of ActionPeroxidase inhibitors Orphan Drug StatusYes – Multiple system atrophy Phase IIIMultiple system …

Read more

It’s only fair to share… ABX-464 Molecular FormulaC16H10ClF3N2O Averrage mass338.712 Da SPL-464 1258453-75-6 [RN] 26RU378B9V 2-Quinolinamine, 8-chloro-N-[4-(trifluoromethoxy)phenyl]- 8-Chloro-N-[4-(trifluoromethoxy)phenyl]-2-quinolinamine EX-A3322, DB14828, SB18690, BS-14770 Abivax is developing ABX464 a lead from HIV-1 splicing inhibitors, which modulates biogenesis of viral RNA, and acts by targeting the Rev protein, for treating HIV infection, rheumatoid arthritis, ulcerative colitis and COVID-19 infection. In August 2021, …

Read more

It’s only fair to share… OTESECONAZOLE VT 1161 オテセコナゾール; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol C23H16F7N5O2   527.4 Synonyms VT 1161 Oteseconazole 1340593-59-0 Other Names (αR)-α-(2,4-Difluorophenyl)-β,β-difluoro-α-(1H-tetrazol-1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridineethanol (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,3,4-tetrazol-1-yl)- 1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol  UPDATE MAY 2022… FDA APPROVED 2022/4/26, Vivjoa Oteseconazole, sold under the brand name Vivjoa, is a medication used for the treatment of vaginal yeast infections.[1] It was approved for medical use in the United States in …

Read more

It’s only fair to share… Nangibotide LQEEDAGEYGCM-amide CAS 2014384-91-7 Molecular FormulaC54H82N14O22S2 Average mass1343.439 Da 2014384‐91‐7 L-Leucyl-L-glutaminyl-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl-L-methioninamide LR 12 peptide LQEEDAGEYG CM L-Leucyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl-L-methionine L-Methionine, L-leucyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl- нангиботид مانغيبوتيد 南吉博肽 Sequence (one letter code) LQEEDAGEYGCM-amide Sequence (three letter code) H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH2 OriginatorInotrem ClassAnti-infectives; Anti-inflammatories; Anti-ischaemics; Antivirals; Peptides Mechanism of ActionTREML1 protein inhibitors Phase II/IIICOVID 2019 infections Phase IISeptic shock Phase …

Read more

It’s only fair to share… PRN 1008, Rilzabrutinib CAS 1575591-66-0 リルザブルチニブ; C36H40FN9O3, MW 665.7597 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Anti-inflammatory disease, Autoimmune disease treatment OriginatorPrincipia Biopharma Class2 ring heterocyclic compounds; Amines; Anti-inflammatories; Fluorobenzenes; Nitriles; Phenyl ethers; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules Mechanism of ActionAgammaglobulinaemia tyrosine kinase inhibitors Orphan Drug StatusYes – Idiopathic thrombocytopenic purpura; Pemphigus vulgaris Phase …

Read more

It’s only fair to share… DEUCRAVACITINIB BMS-986165 CAS 1609392-27-9, C20H22N8O3, 425.46 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide Tyk2-IN-4 UNII-N0A21N6RAU N0A21N6RAU GTPL10432 EX-A3154 BDBM50507816 NSC825520 s8879 OriginatorBristol-Myers Squibb ClassAmides; Aniline compounds; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Ethers; Hepatoprotectants; Organic deuterium compounds; Pyridazines; Skin disorder therapies; Small molecules; Triazoles Mechanism of ActionTYK2 kinase inhibitors Phase IIIPlaque psoriasis Phase IICrohn’s disease; Lupus nephritis; Psoriatic arthritis; Systemic …

Read more